Tags : Manufacture


Y-Biologics Signs a License Agreement with 3D Medicines for YBL-013

Shots: Y-Biologics to receive ~$2M up front and eligible to receive ~$85M as development, regulatory, & commercialization milestones along with royalties on sales in the territory 3D Medicines will get an exclusive right to develop, manufacture, and commercialize YBL-013 in China with the expansion of collaboration in the US and other regions Both the companies […]Read More


Novartis Signs a License Agreement with Mesoblast to Develop and

Shots: Mesoblast to receive $25M up front and $25M as equity investment with additional payments and royalties on achievement of development, regulatory and commercial milestones Novartis to acquire the exclusive WW rights to develop, commercialize & manufacture remestemcel-L for ARDS & access to a cell-therapy based platform with WW rights to a range of potential […]Read More

COVID-19 Pharma

AstraZeneca Signs an Agreement with Catalent to Manufacture AZD1222 for

Shots: Catalent Biologics will provide vial filling and packaging capacity to AstraZeneca at its manufacturing facility in Italy and prepare for large-scale commercial supply of AZD1222 The agreement ramps up the production of AZD1222 and will prepare the facility to enable round-the-clock manufacturing schedules and supply hundreds of millions of doses of AZD1222 from Aug’2020 […]Read More

Biotech COVID-19

Moderna Signs a Ten-Year Worldwide Agreement with Lonza to Manufacture

Shots: :stohththShots: The companies intend to establish manufacturing suites at Lonza’s facilities in the US and Switzerland to manufacture mRNA-1273 at both sites. The collaboration will deploy Lonza’s global expertise in technology transfer and manufacturing while the technology transfer expected to begin in Jun’2020 The focus of the collaboration is to enable the manufacturing of […]Read More


WuXi ATU and GeneMedicine Collaborate to Develop and Manufacture Oncolytic

Shots: WuXi ATU to provide overall process development, viral bank manufacturing, viral stock characterization and cGMP commercial manufacturing and IND filing services via its Oncolytic Virus CDMO platform, to accelerate the development and commercialization of Gene Medicine’s oncolytic virus products The collaboration allows GeneMedicine to advance its pipeline products from the clinical stage to commercialization […]Read More


Prevail Signs an Agreement with Lonza to Develop and Manufacture

Shots: Pevail and Lonza to work collaboratively for process and analytical development plus large-scale production using the baculovirus/Sf9 process for late-stage clinical and commercial supply at Lonza’s GMP facility in Houston. Lonza to manufacture Prevail’s pipeline of novel AAV-based gene therapy programs for neurodegenerative diseases at its gene therapy center of excellence in Houston, TX […]Read More